Drug intelligence / Profile preview

valproic acid + ertapenem

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral (valproic Acid), Intravenous (ertapenem)
01

Overview

This is a combination of two drugs, valproic acid and ertapenem. Valproic acid is an antiepileptic drug primarily used to treat epilepsy and bipolar disorder by increasing gamma-aminobutyric acid (GABA) levels in the brain, thereby stabilizing neuronal activity. Ertapenem is a carbapenem-class broad-spectrum beta-lactam antibiotic used to treat various serious bacterial infections. When administered together, this combination results in a clinically significant drug-drug interaction where ertapenem markedly reduces plasma concentrations of valproic acid, likely by inhibiting the enzyme acylpeptide hydrolase responsible for converting valproic acid-glucuronide back to active valproic acid. This leads to subtherapeutic levels of valproic acid and increases the risk of breakthrough seizures or loss of seizure control. The interaction is considered highly clinically significant; co-administration should generally be avoided unless no alternatives exist[1][2][3][4][5].

02

Targets

ABAT (4-aminobutyrate aminotransferase)PBP (Penicillin-binding protein family)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on valproic acid + ertapenem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valproic acid + ertapenem.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call